Search

Patient organizations

EHA greatly values the collaboration with patient organizations in a growing number of areas, from joint advocacy and a strong presence at the EHA Annual Congress – with a prominent place for the EHA-Patient Joint Symposium on policy and regulatory…

Last chance: special EAPM2017 registration offer for EHA members

Oct 18 2017

EAMP2017 will take place in Belfast, Ireland, from 27-29 November 2017. The European Alliance for Personalised Medicine (EAPM), launched in March 2012, brings together European healthcare experts and patient advocates involved with major chronic diseases.

Nomination criteria

General criteriaOur refreshed EHA Awards program is designed to recognize and encourage the extraordinary achievements of individuals across the field of hematology. Eligibility
To nominate or be nominated, you must be an EHA member.

EHA Kick-off Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.